Study on the relationship between the Polycomb Repressor Complex 2 protein complex core protein EZH2 and triple negative breast cancer

Objective To investigate the expression of Complex Polycomb Repressor 2 (PRC2) protein complex core protein EZH2 in triple negative breast carcinoma, and the association with tumor progression. Methods The clinical data of 110 cases with breast carcinoma between May 2010 and July 2014 were collected, with thirty-six cases of triple negative breast cancer (TNBC) and 76 cases of non-TNBC, to determine the expression of EZH2 with age, tumor size, lymph node metastasis, pathological grading, and clinical staging. Results The positive rate of EZH2 in non-TNBC Group was 45.9% and 77.8% in TNBC Group (χ2=9.97, P<0.01). EZH2 expression in TNBC was related to such factors as patient age, tumor size, lymph node pathological grading, clinical staging, and metastasis. In non-TNBC, tumor size, lymph node metastasis, and pathological grading were related factors. Conclusion The expression of EZH2 in TNBC has a certain relation with age, tomor size, lymph node metastasis, clinical staging, and is likely to be a tumor marker for the early diagnosis, treatment and prognosis for TNBC. Key words: EZH2; Breast carcinoma; Triple negative breast cancer